Shots:
The P-III (POETYK PSO) LTE trial evaluates deucravacitinib (6mg, qd) in 1221 patients with PsO. Enrolled patients were received 1 dose of deucravacitinib
The results showed the durable efficacy & consistent safety profile with that observed in prior P-III (POETYK PSO-1 & 2) trials, clinical efficacy was maintained through ~2yrs. with response rates for PASI 75 & sPGA 0/1 (77.7% & 58.7%) @60wk., treatment discontinuation due to SAEs & AEs remained low for ~2yrs. with no safety signals
Deucravacitinib is the 1st selective allosteric TYK2 inhibitor & is currently under regulatory review in multiple regions including the US, EU & Japan for PsO & under MHRA for PsO, pustular psoriasis & EP
Ref: Businesswire | Image: BMS
